Literature DB >> 15813815

Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.

F Puggioni1, S R Durham, J N Francis.   

Abstract

BACKGROUND: Monophosphoryl lipid A (MPL) is a nontoxic derivative of the lipopolysaccharide (LPS) of Salmonella minnesota R595. MPL has been used as an adjuvant in grass and tree pollen vaccines for the treatment of seasonal allergic rhinitis. Little is known about the influence of MPL on cellular responses to allergens in man. We therefore studied the effects of MPL in vitro on peripheral blood mononuclear cells (PBMC) obtained from patients with grass pollen hay fever.
METHODS: The PBMCs from 13 subjects were cultured with grass pollen Phleum pratense extract (0, 2 and 20 microg/ml) and MPL (0 and 10 microg/ml; defined as an optimal concentration in preliminary studies) and after 6 days proliferative responses were measured by thymidine incorporation and cytokine production by enzyme-linked immunosorbent assay (ELISA).
RESULTS: Proliferative responses were unaffected by the presence of MPL whereas MPL induced a significant increase in allergen-induced interferon (IFN)-gamma production [allergen alone, 645 +/- 466 pg/ml (mean +/- SE) vs allergen + MPL, 3232 +/- 818 pg/ml; P < 0.001]. In addition, there was a significant decrease in interleukin (IL)-5 production (4307 +/- 1030 pg/ml vs 2997 +/- 826 pg/ml; P < 0.01). Although MPL alone could induce modest increases in IL-10 production, MPL did not influence the production of this cytokine in allergen-stimulated cultures. Addition of neutralizing antibody against IL-12 resulted in 95% inhibition of MPL-induced IFN-gamma production. Depletion of monocytes from the culture system abrogated the effects of MPL on elevated cytokine production.
CONCLUSIONS: In summary, use of MPL with grass pollen extract results in immune deviation of allergen-induced peripheral Th2-cell responses in favour of 'protective' Th1 responses in an IL-12 and monocyte-dependent fashion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813815     DOI: 10.1111/j.1398-9995.2005.00762.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  30 in total

Review 1.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 2.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

Review 3.  [Specific immunotherapy for allergic rhinitis. Current methods and innovative developments].

Authors:  O Pfaar; L Klimek
Journal:  HNO       Date:  2008-08       Impact factor: 1.284

Review 4.  Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

Authors:  Jasper H Kappen; Stephen R Durham; Hans In 't Veen; Mohamed H Shamji
Journal:  Ther Adv Respir Dis       Date:  2016-09-27       Impact factor: 4.031

5.  Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS.

Authors:  Ryan Stark; Hyehun Choi; Stephen Koch; Fred Lamb; Edward Sherwood
Journal:  Innate Immun       Date:  2014-12-24       Impact factor: 2.680

6.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

7.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

8.  Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Authors:  Jeroen Geurtsen; H Alexander Banus; Eric R Gremmer; Henke Ferguson; Liset J J de la Fonteyne-Blankestijn; Jolanda P Vermeulen; Jan A M A Dormans; Jan Tommassen; Peter van der Ley; Frits R Mooi; Rob J Vandebriel
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

Review 9.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

10.  Antigen-pulsed bone marrow-derived and pulmonary dendritic cells promote Th2 cell responses and immunopathology in lungs during the pathogenesis of murine Mycoplasma pneumonia.

Authors:  Nicole A Dobbs; Xia Zhou; Mark Pulse; Lisa M Hodge; Trenton R Schoeb; Jerry W Simecka
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.